SOURCE: RefleXion Medical


September 15, 2014 17:02 ET

RefleXion Medical Awarded $1.5MM SBIR Phase II Grant From the National Cancer Institute

Major Support From National Cancer Institute to Accelerate Development of Biologically-Guided Radiotherapy System

BURLINGAME, CA--(Marketwired - September 15, 2014) - RefleXion Medical Inc. announced today that it has been awarded a $1.5MM Small Business Innovation Research (SBIR) Phase II grant from the National Cancer Institute (NCI).

During the 27 month project, entitled "Rotating PET and linear accelerator system for PET-guided radiation therapy," RefleXion will continue development of its revolutionary biologically-guided radiotherapy system for cancer treatment.

"The SBIR Phase II award from the National Cancer Institute validates the potential of RefleXion's PET-guided system and is crucial support complementing our existing venture capital financing," said Dr. Samuel Mazin, the Principal Investigator on the grant and President of RefleXion.

"The RefleXion system will enable simultaneous PET imaging and delivery of therapeutic radiation in a fast rotating gantry," said Dr. David Townsend, Co-inventor of the combined PET/CT scanner and Director at A*STAR-NUS Clinical Imaging Research Centre, Singapore, "I am very excited to be contributing to RefleXion's ground-breaking program as a grant Co-investigator."

"Biologically-guided and personalized radiotherapy would result in improved tumor targeting and reduced toxicity, representing a logical evolution in cancer treatment and could open up significant new clinical applications," said Dr. Jim Welsh, Associate Professor of Radiation Oncology at The University of Texas MD Anderson Cancer Center and a member of RefleXion's Scientific Advisory Board.

About RefleXion Medical:
RefleXion Medical is a privately held medical device company developing the first biologically-guided radiation therapy system for cancer treatment. By leveraging Positron Emission Tomography (PET) in a novel way, RefleXion's patented technology will allow tumors to continuously signal their location during treatment and potentially revolutionize the practice of radiation oncology. Funding for portions of RefleXion's research efforts comes from the National Cancer Institute at the National Institutes of Health, part of the U.S. Department of Health and Human Services (R43CA153466 and R44CA153466). RefleXion is backed by premier venture capital firms Sofinnova Partners, Pfizer Venture Investments and Venrock. For more information, visit and follow @reflexionmed on Twitter.

Contact Information

  • Contact Information:
    Akshay Nanduri
    RefleXion Business Development